Term
when do acute exacerbations not need to be treated? |
|
Definition
when dont result in function decline |
|
|
Term
if treating for acut excaerbation what d you give |
|
Definition
methylprednisolone 500 mg IV x 3 days |
|
|
Term
what is the benefit of giving steroid with acute exacerbatin-3 |
|
Definition
shorten length of exacerb delay tiem til next occurance reduce edema |
|
|
Term
what are first line theapies for disease modifying-3 |
|
Definition
interferon B1b and interferon B1a and glatiramer acetate |
|
|
Term
|
Definition
reduce annual replase rates and MRI burden slow brain atrophy and cogntivie decline |
|
|
Term
|
Definition
reduce interferon secrection by lymphocytes suppress T cell and BBB permeability increase CD56 antural killer cells and Treg cells |
|
|
Term
|
Definition
elevated LFTs decrease CBC injection site depression thyroid |
|
|
Term
monitoring for interferons-3 |
|
Definition
CBC 1 mo,q 3 mo, then q6 LEFTs same as above neutralizing antibody testing |
|
|
Term
|
Definition
|
|
Term
|
Definition
25 mcg SQ every toher day |
|
|
Term
|
Definition
|
|
Term
|
Definition
22 or 44 mcg SQ three times weekly |
|
|
Term
what is the pearl about IFN B1a meds |
|
Definition
refridge, but can be at room temp for 30 days |
|
|
Term
|
Definition
|
|
Term
|
Definition
reduce relapse rate by 30% and releive MRI burdern |
|
|
Term
which drug may slow progression of relapse/remitting MS? |
|
Definition
|
|
Term
which drug cna you use safely for 10 yrs |
|
Definition
|
|
Term
|
Definition
polypet of L alaline, glut, lysine, tyroinse mimics myelin basic protein (MBP) induce T suppressor cell for mylin induce BDNF for neuroprotection |
|
|
Term
|
Definition
injection site one time chest tightening/flushing |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
reduce CNS lesion by 90% decrease relapse by 60% slow progression of disability |
|
|
Term
|
Definition
humanized mono antibody attached very late antigen to block VCAM-1 and decrease lympohcyte entry thru BB |
|
|
Term
|
Definition
injection site devleop neutralizing antibodies rare PML |
|
|
Term
monitoring for natiluzamb |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
which drug decreases relapse by 50% |
|
Definition
|
|
Term
|
Definition
sphingosine 1 phos recpt agonist requesters lymphocytes into 2nd lymph organs |
|
|
Term
|
Definition
LEFTs lymphopenia macular edema ifx |
|
|
Term
monitoring for fingolimod-3 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
which drug is last line agent why? |
|
Definition
mitoxantrone cardiac toxnad leukemia |
|
|
Term
mitoxantrone is FDA approvedd for-3 |
|
Definition
neuro disability in secondary porgressive MS, primary progressive, or woresning relapse |
|
|
Term
mitoxantone is 15 min IV infusion q 3 months* |
|
Definition
|
|
Term
montioring for mitoxantrone-2 |
|
Definition
ECG and LVF befoer ea/ infusion |
|
|
Term
|
Definition
UTI, resp infx, alopecia, menstrual |
|
|
Term
which med doesnt ahve FDA approval |
|
Definition
|
|
Term
|
Definition
baclofen tizandine gabapentin |
|
|
Term
|
Definition
antimuscarinic- oxybutyin, trospium prazosin |
|
|
Term
|
Definition
|
|
Term
tx for depression which agents do you watch fro this closely in? |
|
Definition
antidepressents interferons and natiluzumab |
|
|
Term
|
Definition
|
|
Term
tx for sex dysfunction (only for men)-3 |
|
Definition
taldalifil sildenifil, vardenifil |
|
|
Term
|
Definition
modafinil amantafine amphetamines |
|
|
Term
tx for impaired cognition-2 |
|
Definition
stimulants cholintesterase inhbitiors |
|
|